17 February 2022>: Articles
Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report
Unusual clinical course, Challenging differential diagnosis, Diagnostic / therapeutic accidents, Management of emergency care, Unexpected drug reaction, Educational Purpose (only if useful for a systematic review or synthesis)
Sara Al-Rasbi A , Juhaina Salim Al-Mqbali A* , Rajaa Al-Farsi B , Moza Ali Al Shukaili B , Maryam H. Al-Riyami E , Zubaida Al Falahi E , Hatem Al Farhan A , Abdullah M. Al Alawi ADOI: 10.12659/AJCR.934399
Am J Case Rep 2022; 23:e934399
Table 2. Results summary of the hospitalization microbiology tests.
Test | Result |
---|---|
Respiratory viral screen (including: Rhinovirus PCR, RSV PCR, Adenovirus RVS, Enterovirus RVS, H1N1 confirmatory PCR, Human Metapneumovirus PCR, Parechoviruses, Human Bocavirus, Influenza A and B PCR, Corona viruses 229, 63 and 43 HKU PCR, Parainfluenzae 1,2,3,4 PCR) | Negatives |
Mycoplasma pneumonia PCR | Negative |
Urinary antigen (Legionella) | Negative |
Urinary antigen (pneumococcus) | Negative |
Pneumocystis PCR | Negative |
Cytomegalovirus serology (CMV) | Negative |
Epstein Barr Virous Serology (EBV) | Negative |
Toxoplasma Serology | Negative |
HIV 1&2 Ag/Ab | Negative |
Urine culture | Negative |
Blood culture | Negative |
Sputum culture | Negative |
Mycobacterium Tuberculosis (TB) gene Expert | Negative |
Aspergillus Galactomannan Antigen | Negative |